Stallergenes opens allergen facility
French biopharmaceutical firm Stallergenes has officially inaugurated its new pharmaceutical allergen production facility, claimed to be the largest in the world, in the Paris area. Designed to comply with the most stringent European Medicines Agency (EMEA) and US Food and Drug Administration standards, the plant will make desensitization treatments for all markets, primarily in Europe and North America.
The new unit involved an investment of some 20.0 million euros ($28.4 million) and will incorporate the manufacture of active substance for the firm's Oralair Grasses tablets and increase production capacity for Staloral allergen extracts to meet the needs of an expanding international marketplace. For Stallergenes, "this new production unit will help the company break into the tough US market and increase its production 10-fold," says chief executive Albert Saporta.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze